探討人類微小病毒B19病毒樣顆粒對多形性膠質母細胞瘤細胞的影響

人類細小病毒B19 (B19V) 屬於DNA病毒中的細小病毒科，無外套膜，具正二十面體結構，大小約22-26 nm。病毒殼體 (capsid) 主要由VP1和VP2兩種結構蛋白組成。先前研究顯示，VP2殼體蛋白可自行組裝成病毒樣顆粒 (Virus-like particles, VLPs），並已應用於乳腺癌模型治療的研究。而人類多形性膠質母細胞瘤是成人最常見且侵襲性和復發性高的惡性腦瘤，患者平均存活期僅15個月。雖然目前一線化療藥物替莫唑胺 (Temozolomide, TMZ) 具有一定的療效，但仍伴有副作用，且易產生抗藥性。因此，本論文探討微小病毒B19樣顆粒對人類多形性膠質母細胞瘤細胞的影響。研究結果顯示, VLPs對多形性膠質母細胞瘤細胞及替莫唑胺耐藥腫瘤細胞之生長、遷移及侵襲性具有顯著抑制效果。

Human parvovirus B19 (B19V) belongs to the Parvoviridae family of DNA viruses. It is non-enveloped, has an icosahedral structure, and is approximately 22-26 nm in size. The B19V capsid is mainly composed of two structural proteins, VP1 and VP2. Previous studies have shown that the VP2 capsid protein can self-assemble into virus-like particles (VLPs) and be used to treat mouse models of breast cancer. Human glioblastoma multiforme is the most common, aggressive, and recurrent malignant brain tumor in adults, with an average survival of only 15 months. Currently, the first-line chemotherapy drug temozolomide (TMZ) has some efficacy, but it still has side effects and can lead to drug resistance. Therefore, this study will investigate the effects of B19V VLPs on human glioblastoma multiforme. The results showed that VLPs can effectively inhibit the growth, migration, and invasion of glioblastoma cells and temozolomide-resistant cells.